Work

Incidence and predictors of exceptional response (ExRes) in patients (pts) initiating first-line (1L) treatment for HER2-positive (HER2+) metastatic breast cancer (MBC).

Year: 2025

Type: article

Study design: Observational Study

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e13021

Authors: Sarah L. Sammons, Jose Pablo Leone, Thibaut Sanglier, Jocelyn Sun, Peter Lambert, Raf Poppe, Estefania Monturus, Adam Knott, Eleonora Restuccia, Nancy U. Lin, Sara M. Tolaney

Institutions: Dana-Farber Cancer Institute, Roche (Switzerland), Genentech, Roche (United Kingdom)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: F. Hoffmann-La Roche

OpenAlex ID: W4410822129

FWCI:

Cites:

Cited by:

Related to: 10